BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34117554)

  • 1. Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma.
    Yugawa K; Itoh S; Yoshizumi T; Morinaga A; Iseda N; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Int J Clin Oncol; 2021 Oct; 26(10):1901-1910. PubMed ID: 34117554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8
    Miyazaki K; Morine Y; Imura S; Ikemoto T; Saito Y; Yamada S; Tokuda K; Okikawa S; Yamashita S; Oya T; Tsuneyama K; Shimada M
    Surg Today; 2021 Dec; 51(12):1985-1995. PubMed ID: 34009433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative HALP score is a prognostic factor for intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection: association with sarcopenia and immune microenvironment.
    Toshida K; Itoh S; Nakayama Y; Tsutsui Y; Kosai-Fujimoto Y; Tomino T; Yoshiya S; Nagao Y; Harada N; Kohashi K; Oda Y; Yoshizumi T
    Int J Clin Oncol; 2023 Aug; 28(8):1082-1091. PubMed ID: 37247134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Mod Pathol; 2021 Apr; 34(4):798-807. PubMed ID: 33077921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
    Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
    World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of Lymphocyte-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
    Yugawa K; Maeda T; Kinjo N; Kawata K; Ikeda S; Edahiro K; Edagawa M; Omine T; Kometani T; Yamaguchi S; Konishi K; Tsutsui S; Matsuda H
    J Gastrointest Surg; 2022 Jan; 26(1):104-112. PubMed ID: 34258673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study.
    Lu LH; Zhong C; Wei W; Li SH; Mei J; Zou JW; Guo RP; Zhang YF
    Liver Int; 2021 Feb; 41(2):378-387. PubMed ID: 32562336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
    J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma.
    Lan C; Kitano Y; Yamashita YI; Yamao T; Kajiyama K; Yoshizumi T; Fukuzawa K; Sugimachi K; Ikeda Y; Takamori H; Miyanari N; Hirota M; Baba H
    Br J Cancer; 2022 Feb; 126(2):219-227. PubMed ID: 34616011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of lymphocyte-C-reactive protein ratio in patients with liver cancer: a meta-analysis.
    Shao YJ; Yu GD; Zhang X; Ran YG; Li JH
    Biomark Med; 2023 May; 17(10):497-507. PubMed ID: 37526144
    [No Abstract]   [Full Text] [Related]  

  • 13. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.
    Ye Y; Zhou L; Xie X; Jiang G; Xie H; Zheng S
    J Surg Oncol; 2009 Nov; 100(6):500-4. PubMed ID: 19697355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic roles of leptin-signaling proteins, PD-L1, and tumor-infiltrating lymphocytes in surgically-resected biliary tract cancers.
    Byeon SJ; Chang MS; Cho HJ; Park JH; Kim KH; Park JH; Choi IS; Kim W; Han DS; Ahn HS; Heo SC
    J Surg Oncol; 2023 Mar; 127(4):587-597. PubMed ID: 36367404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma.
    Mocan LP; Craciun R; Grapa C; Melincovici CS; Rusu I; Al Hajjar N; Sparchez Z; Leucuta D; Ilies M; Sparchez M; Mocan T; Mihu CM
    Cancer Immunol Immunother; 2023 Apr; 72(4):1003-1014. PubMed ID: 36251029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status.
    Yugawa K; Itoh S; Iseda N; Kurihara T; Kitamura Y; Toshima T; Harada N; Kohashi K; Baba S; Ishigami K; Oda Y; Yoshizumi T; Mori M
    Sci Rep; 2021 Mar; 11(1):5845. PubMed ID: 33712681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
    Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
    J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis.
    Gong ZJ; Cheng JW; Gao PT; Huang A; Sun YF; Zhou KQ; Hu B; Qiu SJ; Zhou J; Fan J; Yang XR
    Oncologist; 2019 Jul; 24(7):997-1007. PubMed ID: 30910867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
    Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
    Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between microvessel count and postoperative survival in patients with intrahepatic cholangiocarcinoma.
    Nanashima A; Shibata K; Nakayama T; Tobinaga S; Araki M; Kunizaki M; Takeshita H; Hidaka S; Sawai T; Nagayasu T; Tagawa T
    Ann Surg Oncol; 2009 Aug; 16(8):2123-9. PubMed ID: 19434454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.